Investigating genetic changes and targeted treatments for Adult T-cell leukemia in North America
Official title: Epigenetic Alterations and Targeted Therapies in North American ATLL
Funded at Albert Einstein College of Medicine · NIH-11062477 · Data updated 2026-11-12
This study is looking at how the genes of people with Adult T-cell leukemia/lymphoma (ATLL) in North America differ from those in Japan, to find new ways to treat this serious cancer caused by a virus, and it’s designed for patients who want to learn more about potential new treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $551,261 |
| NIH project number | 5R01CA266847-03 |
| Project ID | NIH-11062477 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Adult T-cell leukemia/lymphoma, particularly those who are HTLV-1 carriers.
✕Less likely to help
Patients with other types of leukemia or those not infected with HTLV-1 may not benefit from this research.
What this research studies
This research focuses on Adult T-cell leukemia/lymphoma (ATLL), a serious condition affecting patients with human T-lymphotropic virus-1 (HTLV-1). The study aims to understand the genetic alterations that occur in North American patients compared to those in Japan, particularly looking at mutations that affect epigenetic modifications. By analyzing patient samples, the researchers hope to identify new therapeutic strategies that could improve treatment outcomes for this aggressive cancer. The approach includes targeted sequencing and assessing the sensitivity of cancer cells to specific inhibitors.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective targeted therapies for Adult T-cell leukemia, significantly improving survival rates.
How similar studies have gone: While there has been significant research on ATLL in Japan, this specific focus on North American patients and their unique genetic profile is relatively novel.
Where this research is happening
-
Albert Einstein College of Medicine
Bronx, United States Active
Researchers
- Principal investigator: Ye, Bihui Hilda — Albert Einstein College of Medicine
- Study coordinator: Ye, Bihui Hilda
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.